Compare DEI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | MESO |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2006 | N/A |
| Metric | DEI | MESO |
|---|---|---|
| Price | $11.20 | $19.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $15.29 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.9M | 218.4K |
| Earning Date | 02-03-2026 | 02-25-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,000,336,000.00 | $17,198,000.00 |
| Revenue This Year | $2.82 | $576.59 |
| Revenue Next Year | $1.67 | $41.15 |
| P/E Ratio | $92.66 | ★ N/A |
| Revenue Growth | 3.61 | ★ 191.39 |
| 52 Week Low | $10.79 | $9.61 |
| 52 Week High | $18.96 | $21.00 |
| Indicator | DEI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 60.87 |
| Support Level | $10.79 | $17.90 |
| Resistance Level | $11.26 | $18.73 |
| Average True Range (ATR) | 0.26 | 0.56 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 46.93 | 70.00 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.